Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06163677 Withdrawn - COVID-19 Clinical Trials

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.

Start date: January 17, 2024
Phase:
Study type: Observational

The main purpose of this study is to understand: - the symptoms of COVID-19 or influenza - health-related outcomes of people with COVID-19 or influenza - the effects of vaccines in people with COVID-19 or influenza. This study will take in participants who are: - 18 years or older - reported to have symptoms with lab tests that have confirmed illness. The lab tests can be tested at any of Walgreens pharmacy COVID-19 or influenza test sites. The study will collect vaccine history information from participants who are ready to take part in the study. Participant will be emailed a form with questions about their health related to COVID-19 or influenza during twelve follow-ups over a 6-month period.

NCT ID: NCT05035680 Withdrawn - Influenza Clinical Trials

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Start date: July 14, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to characterize safety and tolerability of the squalene-based adjuvant candidate SWE and its potential to enhance the immune response to seasonal influenza vaccine antigens in healthy older adults.

NCT ID: NCT04806529 Withdrawn - Influenza Clinical Trials

An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older

Start date: December 15, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and Control (ECDC) COVID 19 case definition. The co-primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent virologically confirmed symptomatic COVID 19 defined by the US Food and Drug Administration (FDA) guidance.

NCT ID: NCT04761692 Withdrawn - Covid19 Clinical Trials

Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

This proposed study seeks to community knowledge and understand the experience of underserved communities in the exploration of reducing health disparities and increasing vaccine uptake and acceptability COVID-19, influenza, and pneumonia for AA and Latinx populations. Unique in its design, it has the following characteristics: 1) multifaceted, 2) culturally tailored, 3) community-based, and 4) mixed methods in which the outcomes of interest will be measured before and after the intervention with 18-month interval. Furthermore, we seek to enhance our partnerships and collaborations with churches in South Los Angeles by supporting efforts to encourage COVID-19, influenza, and pneumonia vaccination uptake among underserved minorities in one of the most challenged and hard-to-reach population areas in the nation.

NCT ID: NCT03924284 Withdrawn - Influenza A Virus Clinical Trials

Novel Assays for Detection of Influenza Virus

Start date: April 18, 2019
Phase:
Study type: Observational

Seasonal influenza virus causes an estimated 0.3-0.6 million deaths per year. Avian influenza virus H5N1, H7N9 and H5N6 has fatality rate of over 30%. Swine influenza viruses from pigs have also infected humans. Molecular assays are now used routinely in the detection of influenza viruses. The M gene is often used as the target for all influenza A viruses because the nucleotide sequence of this gene is relatively conserved among all the influenza A viruses. The World Health Organization and the US Centers for Disease Control and Prevention (CDC) have published protocols for molecular detection of influenza A virus M gene. However, recent studies have shown that mutations in the M gene have led to a reduced sensitivity of RT-PCR assay targeting this gene. Therefore, it is important to use alternative conserved genes as the target of RT-PCR. In this study, our aim is to evaluate two new RT-PCR assays that are based on PB2 and NS gene segment.

NCT ID: NCT03903718 Withdrawn - Influenza Clinical Trials

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

Start date: April 3, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of MEDI8852 for the treatment of influenza caused by a wild type A/H1N1 challenge strain in healthy, influenza serosusceptible adults.

NCT ID: NCT03898973 Withdrawn - Influenza Clinical Trials

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood

FLU-LN
Start date: April 11, 2019
Phase: Phase 4
Study type: Interventional

This is one project of a larger ongoing study related to the immune system's response to the flu virus. This study is designed to determine how immune memory develops at the actual site of exposure, and how immunization may alter this process.

NCT ID: NCT03884296 Withdrawn - Influenza Clinical Trials

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

FLU-Tonsil
Start date: April 15, 2019
Phase: Phase 4
Study type: Interventional

This is one project of a larger ongoing study related to the immune system's response to the flu virus. This study is designed to investigate the immune response to a nasal flu immunization in tonsillar tissue compared to what can be measured in the blood.

NCT ID: NCT03327987 Withdrawn - Influenza Clinical Trials

Early Flu Shots in SOT

Start date: May 7, 2019
Phase:
Study type: Observational

Although time from transplant has been a factor in vaccine response, there is limited data on immunizations that occur in the first post-transplant year, and there are no data that suggest influenza vaccination early post-transplant may have any adverse effects on the graft. It is suggested that early vaccinations may lead to reduced immunogenicity due to induction immunosuppression. However, not vaccinating patients may leave them vulnerable to influenza infection for a period of time. This study is designed to look at the immunogenicity and side effects of the standard of care influenza vaccine in patients between 31 and 365 days post-transplant.

NCT ID: NCT03028909 Withdrawn - Clinical trials for Influenza - Type A Strains

Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.